Trial reportJournal of cosmetic dermatology2025
Efficacy and Tolerability of a Topical Peptide-Hyaluronic Acid Lip Treatment Using a Novel Delivery System in Subjects With and Without Prior Lip Augmentation.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and Tolerability of a Topical Peptide-Hyaluronic Acid Lip Treatment Using a Novel Delivery System in Subjects With and Without Prior Lip Augmentation.Journal of cosmetic dermatology · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLips are prone to dehydration and aging. Effective noninvasive hyaluronic acid (HA) delivery remains challenging.
aimTo evaluate topical Replenishing Lip Filler-Tiered Release Vesicles (RLF-TRV) in filler-naïve and previously-augmented lips.
methodsTwo single-center trials evaluated efficacy and tolerability of RLF-TRV Serum. Study 1 included filler-naïve subjects or those without lip filler for 12 months. Study 2 enrolled subjects with prior HA lip augmentation (3-9 months earlier) in a double-blind, placebo-controlled design. Participants applied RLF-TRV or placebo twice daily for 3 weeks, followed by a 2-week regression period. Outcomes included grading of shine, texture, and vermilion border, Investigator and Subject Global Aesthetic Improvement Scale (I-GAIS, S-GAIS), and satisfaction. Imaging and tolerability assessments were conducted throughout the study.
resultsRLF-TRV significantly improved lip aesthetics (shine, texture, and vermilion border), with high satisfaction across both studies. In Study 1, 94% of treated participants were "Improved" on I-GAIS (p < 0.001), and 81% were "Much-Improved" on S-GAIS (p < 0.05). In Study 2, 88% of treated participants were "Improved" on both I-GAIS and S-GAIS. RLF-TRV was well tolerated, with no recorded adverse events.
conclusionsRLF-TRV significantly improved lip aesthetics, offering a noninvasive alternative or complementary treatment to injectable procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.